News

29 May 2017

NovaMedica appoints Alexander Kuzin as General Director (CEO)

Russian pharmaceutical company NovaMedica, a portfolio company of RMI, announces the appointment of Alexander Kuzin to the post of Director General (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017

21 April 2017

NovaMedica and Pfizer won the “Platinum Ounce” award in the nomination “Deal of the Year”

NovaMedica, Russian pharmaceutical company, and Pfizer, one of the leaders of the world biopharmaceutical industry, were recognized as winners of the open professional contest “Platinum Ounce” in the nomination “Deal of the Year” for the long-term partnership agreement which envisages construction of a high-technology pharmaceutical production facility and localization of more than 30 life-saving and essential drugs in Russia. 

19 April 2017

NovaMedica launched Technology Center to develop innovative drugs

NovaMedica, a Russian pharmaceutical company (a RMI portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

23 December 2016

Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by RMI and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

10 November 2016

NovaMedica prepares to launch the new drug development laboratories

Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15 mln.                                                  

03 October 2016

Four NovaMedica Executives are in the Top-1000 Russian Managers Rating Released by the Managers Association of Russia and Kommersant Publishing House

Four NovaMedica executives are among the business leaders listed in the Top-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.

13 July 2016

Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.

13 July 2016

Pfizer and NovaMedica announce a strategic partnership in Russia

Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by RMI and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region. 

22 June 2015

Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

18 June 2015

NovaMedica is planning to create around 15 innovative nanotech-involved pharmaceutical products

A Russian pharmaceutical company NovaMedica is planning to grow its R&D activities targeted at building a portfolio of proprietary nanotech-involving pharmaceutical products. This is what has been announced today by Vladimir Gurdus, General Manager at RMI Partners, managing company of NovaMedica, at the Annual Saint Petersburg International Economic Forum during his panel discussion titled “Nanotechnologies – meeting the expectations?”